Microglial cells are the major immune cells of the central nervous system (CNS), and directly
react to neurodegeneration, but other immune cell types are also able to react to pathology …

Alzheimer disease (AD) is the most common type of dementia, and is currently incurable;
existing treatments for AD produce only a modest amelioration of symptoms. Research into …

The pathological processes leading to synapse loss, neuronal loss, brain atrophy and
gliosis in Alzheimer's disease (AD) and their relation to vascular disease and immunological …

Alzheimer's disease (AD) is the most common type of dementia, and no disease-modifying
treatments are available to halt or slow its progression. Amyloid-beta (Aβ) is suggested to …

Deficiency in cerebral amyloid β-protein (Aβ) clearance is implicated in the pathogenesis of
the common late-onset forms of Alzheimer's disease (AD). Accumulation of misfolded Aβ in …

The blood–brain barrier (BBB) is a dynamic and complex interface between blood and the
central nervous system that strictly controls the exchanges between the blood and brain …

To understand how microglial cell function may change with aging, various protocols have
been developed to isolate microglia from the young and aged central nervous system …

Background The blood-brain barrier (BBB) dysfunction represents an early feature of
Alzheimer's disease (AD) that precedes the hallmarks of amyloid beta (amyloid β) plaque …

Patients with Alzheimer's disease (AD) suffer from brain amyloidosis related to defective
clearance of amyloid-β (Aβ) by the innate immune system. To improve the innate immune …

Morgan D.(Alzheimer's Institute, University of South Florida, Tampa, FL, USA)
Immunotherapy for Alzheimer's Disease (Key Symposium). J Intern Med 2011; 269: 54–63 …